Boston Scientific financials
$43.88−0.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.73B | $9.82B | $9.05B | $8.39B |
| Gross profit | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B | $6.45B | $7.62B | $7.01B | $6.46B | $5.96B |
| Gross margin | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | 65.0% | 71.0% | 71.4% | 71.3% | 71.1% |
| Operating income | $3.61B | $2.60B | $2.34B | $1.67B | $1.12B | -$80.0M | $1.52B | $1.51B | $1.28B | $447.0M |
| Net income | $2.90B | $1.85B | $1.57B | $642.0M | $985.0M | -$115.0M | $4.70B | $1.67B | $104.0M | $347.0M |
| Net margin | 14.4% | 11.1% | 11.0% | 5.1% | 8.3% | −1.2% | 43.8% | 17.0% | 1.1% | 4.1% |
| Diluted EPS | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | $-0.08 | $3.33 | $1.19 | $0.08 | $0.25 |
| EBITDA | $5.45B | $4.33B | $3.56B | $3.20B | $3.05B | $1.86B | $2.80B | $2.56B | $2.38B | $2.16B |
| Operating cash flow | $4.53B | $3.43B | $2.50B | $1.53B | $1.87B | $1.51B | $1.84B | $311.0M | $1.43B | $1.18B |
| Free cash flow | $3.66B | $2.64B | $1.79B | $939.0M | $1.32B | $1.13B | $1.38B | -$5.0M | $1.11B | $806.0M |
| Diluted shares | 1,494.5M | 1,485.9M | 1,463.5M | 1,439.7M | 1,433.8M | 1,416.7M | 1,410.6M | 1,401.4M | 1,392.7M | 1,377.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.97B | $414.0M | $865.0M | $928.0M | $1.93B | $1.73B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $11.44B | $10.75B | $9.10B | $8.94B | $9.06B | $9.14B |
| Total assets | $43.67B | $39.40B | $35.14B | $32.47B | $32.23B | $30.78B |
| Total liabilities | $19.20B | $17.39B | $15.61B | $14.90B | $15.61B | $15.45B |
| Shareholders' equity | $24.47B | $22.00B | $19.53B | $17.57B | $16.62B | $15.33B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology